High concentrations of progesterone and mifepristone mutually Reinforce cell cycle retardation and induction of apoptosis

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1053-1058

  Moe, Bjørn G ^a   Vereide, Anne B ^a   Ørbo, Anne ^a   Sager, Georg ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Apoptosis; Cancer; Cell cycle; Endometrium; Growth; Ishikawa cells; Mifepristone; Progesterone

Indexed keywords

MIFEPRISTONE; PROGESTERONE;

APOPTOSIS; ARTICLE; ASSAY; CANCER CELL; CELL CYCLE ARREST; CONCENTRATION RESPONSE; DNA FRAGMENTATION; ENDOMETRIUM CANCER; EXPERIMENTAL STUDY; FEMALE; HUMAN; HUMAN CELL; PHYSIOLOGY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MIFEPRISTONE; PROGESTERONE; PROGESTINS;

EID: 64949128893     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Schafer KA: The cell cycle: a review. Vet Pathol 35: 461-478,1998.
2. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
3. Nakano R: Apoptosis: gene-directed cell death. An overview. HormRes 48: 2-4, 1997.
4. Gal D: Hormonal therapy for lesions of the endometrium. Semin Oncol 13: 33-36, 1986.
5. Graham JD and Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev 18: 502-519, 1997.
6. Simoncini T and Genazzani AR: Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148: 281-292, 2003.
7. Lange CA: Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol 18: 269-278, 2004.
8. Edwards DP: Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67: 335-376,2005.
9. Moe BT, Vereide AB, Jaeger R, Orbo A and Sager G: Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell densities, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res 29: 1047-1052,2009.
10. Holinka CF, Hata H, Kuramoto H and Gurpide E: Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem 24: 85-89, 1986.
11. Brogden RN, Goa KL and Faulds D: Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 45: 384-409, 1993.
12. Boonyaratanakornkit V and Edwards DP: Receptor mechanismsof rapid extranuclear signalling initiated by steroid hormones Essays Biochem 40: 105-120, 2004.
13. Sutherland RL, Hall RE, Pang GYN, Musgrove EA and Clarke CL: Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48: 5084-5091,1988.
14. Formby B and Wiley TS: Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl- 2 and p53. Ann Clin Lab Sci 28: 360-369, 1998.
15. Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ and Zheng W: Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol 79: 169-176, 2000.
16. Nishida M: The Ishikawa cells from birth to the present. Hum CelU5: 104-117,2002.
17. Berthois Y, Katzenellenbogen JA and Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496-2500, 1986.
18. Musgrove EA, Lee CS and Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. MolCell Biol 11: 5032-5043, 1991.
19. Berthelsen E, Endresen P, Orbo A and Sager G: Non-genomic cell growth inhibition by progesterone. Cell cycle retardation and induction of cell death. Anticancer Res 24: 3749-3756, 2004.
20. Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ,Beusman I, Forgez P, Mimoun M and Rostene W: Hormonal regulation of apoptosis in breast cells and tissues. Steroids 65: 593-598, 2000.
21. Yu S, Lee M, Shin S and Park J: Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J Cell Biochem 52:445-451, 2001.
22. Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM and Johansson E: Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod 16: 2103-2108, 2001.
23. Vereide AB, Kaino T, Sager G and Orbo A: Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy A comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 97: 740-750, 2005.
24. Horwitz KB, Wei LL, Sedlacek SM and d'Arville CN: Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res 41: 249-316,1985.
25. Cadepond F, Ulmann A and Baulieu EE: RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48: 129- 156,1997.
26. Leonhardt SA and Edwards DP: Mechanism of action of progesterone antagonists. Exp Biol Med 227: 969-980,2002.
27. Musgrove EA and Sutherland RL: Effects of the progestin antagonist RU 486 on T-47D breast cancer cell cycle kinetics and cell cycle regulatory genes. Biochem Biophys Res Commun 195: 1184-1190,1993.
28. Thomas M and Monet JD: Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab 75: 865-870,1992.
29. Li A, Felix JC, Minoo P, Amezcua CA and Jain JK: Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril 84: 202-211,2005.
30. Navo MA, Smith JA, Gaikwad A, Burke T, Brown J and Ramondetta LM: In vitro evaluation of the growth inhibition andapoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol 62: 483-489,2008.
31. Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-kB in development and progression of human cancer. Virchows Arch 446: 475-482,2005.
32. Paulssen RH, Moe BT, Gronaas H and Orbo A: Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids 73: 116-128, 2008.
33. Orbo A, Moe BT, Gronaas H and Paulssen RH: Early effects of high concentrations of progesterone and mifepristone-A gene expression study of endometrial cancer cells (Ishikawa). J Steroid Biochem Mol Biol 113: 139-149,2009 2009.